NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,451 | -2.9% | 44,441 | -6.4% | 0.00% | – |
| Q2 2023 | $27,246 | -12.5% | 47,467 | +9.2% | 0.00% | – |
| Q1 2023 | $31,121 | -66.4% | 43,470 | +5.2% | 0.00% | – |
| Q4 2022 | $92,520 | -37.1% | 41,332 | -9.7% | 0.00% | – |
| Q3 2022 | $147,000 | -15.5% | 45,762 | +0.4% | 0.00% | – |
| Q2 2022 | $174,000 | -95.0% | 45,570 | -1.9% | 0.00% | -100.0% |
| Q1 2022 | $3,457,000 | +664.8% | 46,452 | +39.1% | 0.01% | +600.0% |
| Q4 2021 | $452,000 | -9.2% | 33,389 | +20.6% | 0.00% | 0.0% |
| Q3 2021 | $498,000 | -29.1% | 27,689 | -32.4% | 0.00% | -50.0% |
| Q2 2021 | $702,000 | +3.1% | 40,958 | +20.2% | 0.00% | 0.0% |
| Q1 2021 | $681,000 | +11.5% | 34,061 | -5.2% | 0.00% | 0.0% |
| Q4 2020 | $611,000 | -5.3% | 35,947 | -7.2% | 0.00% | 0.0% |
| Q3 2020 | $645,000 | -19.7% | 38,719 | +11.7% | 0.00% | -33.3% |
| Q2 2020 | $803,000 | -0.7% | 34,674 | -24.9% | 0.00% | 0.0% |
| Q1 2020 | $809,000 | – | 46,195 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 432,952 | $1,385,000 | 0.91% |
| GREAT POINT PARTNERS LLC | 447,820 | $1,433,000 | 0.34% |
| Birchview Capital, LP | 128,000 | $410,000 | 0.29% |
| Edgestream Partners, L.P. | 1,047,636 | $3,352,000 | 0.26% |
| Rhenman & Partners Asset Management AB | 550,000 | $2,068,000 | 0.22% |
| CM Management, LLC | 50,000 | $160,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 430,037 | $1,376,000 | 0.17% |
| PDT Partners, LLC | 307,953 | $985,000 | 0.15% |
| Virtus ETF Advisers LLC | 72,018 | $230,000 | 0.09% |
| ALGERT GLOBAL LLC | 476,412 | $1,525,000 | 0.09% |